CRANBURY

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study

AETOSWire sarjatha 21 June، 2023

in Patients with Relapsed/Refractory B-cell Malignancies CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on...

Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer

Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer

AETOSWire sarjatha 12 October، 2022

CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence...